Vericiguat for heart failure with CardioMEMS monitoring
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether adding vericiguat to your usual heart failure medicines helps reduce pressure in your lungs and improve symptoms. You will have a CardioMEMS sensor already implanted to monitor your heart, and the study will use its readings to guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a CardioMEMS device implanted for at least 2 weeks.
- You have heart failure with a reduced ejection fraction (less than 45%).
- You have symptoms like shortness of breath or fatigue (NYHA class II-IV).
- Your systolic blood pressure is at least 100 mmHg.
- Your CardioMEMS readings show elevated lung pressure (dPAP > 15 mmHg) for more than 8 days in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
This trial tests whether starting the medication vericiguat soon after a heart attack can help people whose hearts are weakened (ejection fraction 45% or lower) and who developed heart failure. Vericiguat is an oral medicine that may reduce strain on the heart and improve outcomes when given early.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This study is looking at how well the CardioMEMS heart monitor works for people with heart failure. The device is already implanted and tracks pressure in your lung artery to help your doctor manage your condition and potentially prevent hospital visits.
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.